Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome

To assess, in women participating in a breast cancer prevention trialon fenretinide (4-HPR), the relationship of drug and retinol levels with the risk of second breast malignancy, taking into account age and menopausal status. In a multicenter prevention trial, women with early breast cancer were ra...

Full description

Saved in:
Bibliographic Details
Published in:Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2003-01, Vol.12 (1), p.34-41
Main Authors: Formelli, Franca, Camerini, Tiziana, Cavadini, Elena, Appierto, Valentina, Villani, Maria Grazia, Costa, Alberto, De Palo, Giuseppe, Di Mauro, Maria Gaetana, Veronesi, Umberto
Format: Article
Language:English
Subjects:
Adult
Age Factors
Aged
Anticarcinogenic Agents - therapeutic use
Breast Neoplasms - prevention & control
Female
Fenretinide - blood
Fenretinide - therapeutic use
Humans
Italy
Middle Aged
Neoplasm Recurrence, Local - prevention & control
Prognosis
Time Factors
Vitamin A - blood
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess, in women participating in a breast cancer prevention trialon fenretinide (4-HPR), the relationship of drug and retinol levels with the risk of second breast malignancy, taking into account age and menopausal status. In a multicenter prevention trial, women with early breast cancer were randomly assigned to receive no treatment or 200 mg of 4-HPR/day for 5 years. Blood was collected at baseline and on a yearly basis during intervention from women recruited at the Istituto Tumori (Milan, Italy; 818 and 756 in the 4-HPR and control arm, respectively, who accounted for 53% of the participants in the trial). The plasma concentrations of 4-HPR, its main metabolite N-(4-methoxyphenyl) retinamide, and retinol were assayed by high-performance liquid chromatography. Three age ranges (or=56 years), menopausal status at baseline, and disease outcome at a median follow-up of 97 months were taken into account in the analysis. Baseline retinol levels were significantly lower (P
ISSN:1055-9965